First described in 1864 by the German physician Rudolf Virchow and later named in 1910 by James Homer Wright, neuroblastoma (NB) remains an enigma despite decades of research and clinical experience. NB is an incredibly heterogeneous tumor with a natural history that ranges from regression and complete resolution to progression with metastasis and eventual death. The outcomes for patients with low and intermediate risk neuroblastoma has improved, largely through the recognition of the significant therapy related complications and a subsequent reduction in therapy intensity, although the survival for high risk disease remains poor.

Content in this topic is referenced in SCORE Neuroblastoma overview

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 30, 2022